Chemical Nameelosulfase alfa
Dosage FormInjection (intravenous; 5 mg/5 mL (1 mg/mL))
Drug ClassEnzymes
CompanyBioMarin Pharmaceutical Inc.
Approval Year2014


  • Treatment for Mucopolysaccharidosis type IVA (Morquio A syndrome).
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vimizim (elosulfase alfa) Prescribing Information2014BioMarin Pharmaceutical Inc., Novato, CA